What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the ...

Key Points Analyst expectations are far above the prices you'd need to pay now to own a couple of biotechnology stocks.Compass Pathways is developing psilocybin as a treatment for depression.Viking ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...

Dr. Reddy’s Laboratories ( NYSE: RDY) is preparing to launch a generic version of semaglutide, the active ingredient in Novo ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued carePresentations on tau to explore its biological role, the d ...